Loading...
Loading...
Browse all stories on DeepNewz
VisitWhat will be the outcome of Biogen's acquisition proposal for Sage by end of 2025?
Acquisition completed at proposed price • 25%
Acquisition completed at a different price • 25%
Acquisition not completed • 25%
Acquisition rejected • 25%
Official press release from Biogen or Sage Therapeutics, or SEC filings
Biogen Proposes $442 Million Acquisition of Sage Therapeutics at $7.22 Per Share, Offering 30% Premium as Stock Jumps 35%
Jan 13, 2025, 10:30 AM
Biogen Inc. ($BIIB) has made a nonbinding acquisition proposal to Sage Therapeutics ($SAGE), offering $7.22 per share, which represents a 30% premium over Sage's recent trading price. The total value of the proposed acquisition amounts to approximately $442 million. Following the announcement, Sage Therapeutics' stock surged by 35%, reflecting investor optimism regarding the potential deal. Biogen's CEO, Chris Viehbacher, indicated that the company is actively seeking opportunities in the biotech sector, stating, 'We will be doing deals.' While he did not confirm specific targets, he was asked about the possibility of acquiring Stoke Therapeutics, which is preparing for Phase 3 trials for its treatment of Dravet syndrome. The ongoing discussions and market reactions are expected to be highlighted during the upcoming JPMorgan Healthcare Conference.
View original story
Other outcome • 25%
Offer revised • 25%
Acquisition completed • 25%
Offer rejected • 25%
Other actions • 25%
Increase offer • 25%
Proceed with acquisition • 25%
Withdraw offer • 25%
Successful acquisition of Sage Therapeutics • 25%
Multiple acquisitions completed • 25%
No acquisitions completed • 25%
Successful acquisition of another biotech • 25%
Highly volatile with no clear trend • 25%
Underperforms the biotech index • 25%
Performs in line with the biotech index • 25%
Outperforms the biotech index • 25%
Remain between $500M and $600M • 25%
Decrease below $400M • 25%
Decrease to between $400M and $500M • 25%
Increase to over $600M • 25%
Other Outcomes • 25%
Acquisition Delayed • 25%
Acquisition Abandoned • 25%
Acquisition Completed • 25%
Yes • 50%
No • 50%
Increases by more than 50% • 25%
Decreases by more than 10% • 25%
Remains stable (±10%) • 25%
Increases by 30-50% • 25%